Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq)

• Catalog Number: orb1805469
• Category: Antibodies
• Description: Anti-CD79b Reference Antibodyected antibody and Monomethyl auristatin E (MMAE) that can be used in combination with bendamustine and rituximab for the treatment of adult patients with at least two relapses or refractory diffuse large B-cell lymphoma. Polatuzumab vedotin binds to CD79b and is internalized by tumor cells. MMAE is cleaved from cells by lysosomal protease and promotes tumor cell apoptosis by inhibiting microtubule formation.
• Target: CD79b
• Clonality: Monoclonal
• Isotype: IgG
• Conjugation: Unconjugated
• Reactivity: Human
• Buffer/Preservatives: 100 mM Pro-Ac 20 mM Arg pH 5.0
• Purity: > 95%
• MW: 145.5 kDa
• Tested applications: ELISA, FA, FACS, Kinetics
• Endotoxins: < 1 EU/mg
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Note: For research use only

Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

The purity of Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq)is more than 95% ;determined by SEC-HPLC.

Immobilized human CD79b; His Tag at 2 μg/mL can bind Anti-CD79b Reference Antibody (polatuzumab vedotin-piiq);EC50=0.005029μg/mL.